16 February 2026, Preprint v1 · CC-BY 4.0

Qeios

PREPRINT

Review Article

The KHK–Polyol Axis as a Convergent Energetic Bottleneck in Chronic Disease Persistence

Christopher Ryan Mearns[1], **Paul Gross**[2]

1. LIV3 Health, United States; 2. Department of Family Practice, University of British Columbia, Canada

Background: Despite decades of focus on caloric intake and insulin signaling, the global rates of metabolic and neurodegenerative diseases continue to rise. This suggests a fundamental “missing link” in our understanding of cellular energy metabolism. Although various stressors instigate disease, a model that identifies a convergent mechanism capable of preventing cellular recovery across diverse pathologies is lacking.

Claim/Hypothesis: In fructose-permissive states, unregulated fructose phosphorylation via ketohexokinase (KHK) functions as a convergent energetic sink that can (i) acutely deplete ATP and inorganic phosphate and (ii) promote the net loss of adenine nucleotides through AMP deaminase–linked purine degradation to uric acid under repeated or high-flux conditions. We propose that this creates an energetic hysteresis in which cells remain stabilized in a Cell Danger Response (CDR) phenotype, characterized by mitochondrial fission and reduced energetic flexibility, unless a recovery threshold is exceeded.

The Descent into Fragility: This study delineates the physical cascade of energy failure.

- **Engine Stall: KHK-linked ATP/Pi depletion and uric-acid–associated aconitase inhibition bias mitochondrial fission, creating a low-efficiency state resistant to recovery by caloric restriction alone.**
- **Local Spread: Energetic stress may couple with CD38-linked inflammatory circuits, accelerating NAD+ depletion and impairing NAD+-dependent repair programs.**
- **Systemic Triage: Vulnerable hypothalamic nodes may downshift high-cost programs (motivation and reproduction) to prioritize survival-driven foraging physiology.**

The validity of this model rests on the causal necessity of KHK-mediated flux; it would be effectively falsified if metabolic syndrome or hypothalamic energetic failure persists in KHK-deficient human phenotypes (Essential Fructosuria) under identical metabolic stressors.

doi.org/10.32388/R2NFG9

Conclusion: By reframing chronic diseases as a crisis of cellular voltage rather than a surplus of fuel, we provide a unified theory that subsumes existing caloric and hormonal models. The model predicts that targeted modulation of the KHK/CD38 axis may function as a testable circuit-breaking intervention to enable energetic recovery (Table 1).

Correspondence: papers@team.qeios.com — Qeios will forward to the authors

1. Introduction: The Forest of Bio-energetics

1.1. The Shared Signature of Decay

Imagine a city where every building is in disrepair. The windows are cracked, the paint is peeling, and trash is piling up in the streets. If you look at each building individually, you might conclude that they suffer from different problems—one has a roof leak, and another has a broken furnace. But if you look closer, you find a single, shared signature: the city's power grid is stuck in a permanent "brownout." There is simply not enough voltage to operate the power tools required for repair.

This "low-voltage" operation, known as the Cell Danger Response (CDR), characterizes the transition from health to fragility [1]. As proposed by Wallace (2012), the organizing power of energy flow is the basis of biological complexity, and its systemic decline serves as the unifying pathophysiological mechanism for metabolic and neuropsychiatric decay [2]. In this state, cells enter an automated "Eco-Mode," halting renewal to prioritize defense. We propose that while various stressors can instigate this shift, unregulated KHK-mediated flux acts as the metabolic anchor that maintains this state, preventing the system from returning to homeostatic capacity [3].

In this framework, "unifying" refers to a mechanism that (i) is triggered by multiple common stressors, (ii) converges on shared energetic markers (ATP:ADP, ΔG-ATP, NAD+), and (iii) predicts the reversal of persistence when relieved.

1.2. Scope and Applicability

The framework proposed here is intended to be applied primarily to chronic, non-communicable diseases characterized by persistent metabolic stress and impaired energetic recovery, including metabolic, vascular, and neurodegenerative conditions [4].

While this model identifies KHK as a high-leverage energetic amplifier, it is not presented as a universal cause of all pathologies. It does not account for primary genetic mitochondrial disorders, acute trauma-induced energetic failure, or infection-driven sepsis, which are KHK-independent pathways predominate. Furthermore, while the individual nodes of this cascade are rooted in established biochemistry, the systemic propagation described herein remains a systems-level hypothesis that requires further longitudinal validation in human populations (further discussed in Section 6.3). Chronic diseases emerge when energetic recovery is prevented rather than merely delayed. The present model focuses specifically on the mechanisms that stabilize this energetic failure, anchoring cells in a chronic Cell Danger Response [5].

1.3. Note on Terminology

In this paper, we use the term “cellular voltage” as a conceptual shorthand for effective energy charge (the ΔG-ATP and ATP:ADP ratio) and cellular redox capacity (NAD+:NADH pools). After this definition, the term “cellular voltage” is used strictly as a shorthand descriptor and not as a literal electrical measurement.

1.4. The Tipping Point

Standard medical models suggest that this “Eco-Mode” is caused by a surplus of calories or insulin. However, these are downstream effects. The real problem is a physical hole in the battery cell.

We identified the ketohexokinase (KHK) pathway as a high-leverage energetic amplifier of systemic energy failure. We propose that it serves as a common biochemical funnel for both exogenous and endogenous stressors. In this framework, KHK acts as a permissive bottleneck for disease persistence. While myriad factors may instigate a state of cellular defense, the KHK-mediated sink represents a key mechanism that can anchor the cell in a low-voltage state. It serves as a common funnel for two distinct streams of metabolic stress:

- **Exogenous Stream:** Dietary intake of fructose, which bypasses the cell’s “energy governors” (PFK-1) to initiate an immediate stoichiometric drain on ATP [6].
- **Endogenous Stream:** Internally generated fructose produced via the polyol pathway [7]. This stream is activated by “non-sugar” stressors, including high salt intake, alcohol consumption, dehydration, and acute hyperglycemic spikes, effectively turning the liver and brain into internal fructose factories [8].

By acting as the convergence point for these stressors, KHK-mediated flux stabilizes the low-voltage state, creating an energetic choke-point that prevents the cell from meeting the metabolic requirements for repair.

While salt and alcohol act as osmotic triggers, hyperglycemia provides a large substrate mass for the polyol pathway. In states of persistent hyperglycemia, the activation of Aldose Reductase allows a substantial fraction (reported to be up to ~30%) of glucose to be diverted into the polyol-fructose axis, bypassing the regulated glycolytic 'governors' and feeding directly into the KHK stoichiometric sink (schematized in Fig. 1) [7].

1.5. The Goal of This Paper

This study maps the transition from a localized energy leak to a systemic forest fire. We will demonstrate how this “energetic brownout” travels from the liver to the brain, muting our motivation, breaking our vascular health, and spreading like a contagion to the healthy tissues. Finally, we identify the KHK/CD38 axis as a high-leverage metabolic bottleneck and propose that its targeted modulation may serve as a prerequisite for restoring the bio-energetic resilience that characterizes homeostatic health.

We also outline specific, falsifiable predictions at the level of ATP:ADP, ΔG-ATP, NAD+, and mitochondrial morphology, providing a roadmap for the experimental validation of this model.

2. Conceptual Synthesis and Analytical Framework

2.1. The Logic of Scaling

Our model builds upon the Cell Danger Response (CDR) framework, which conceptualizes metabolic disease not as a failure of parts but as a persistent state of cellular defense [1]. To establish this model, we utilized a translational synthesis that bridges three distinct scales of biological observation: the adaptive (seasonal survival) [9], systemic (chronic disease states), and stoichiometric (intracellular energy co-factors) scales. We distinguish between the adaptive activation of the KHK pathway, which allows migratory species to survive scarcity by shifting to a low-voltage, fat-storing state, and the chronic activation seen in modern humans, where salt, alcohol, and hyperglycemia turn this survival switch into a permanent trap [3][1][10][11][12][13].

2.2. The Benign Model: Essential Fructosuria

The strongest evidence for our "Unified Model" is found in the human experiment of Essential Fructosuria [14]. Individuals with this rare genetic deficiency lack the KHK enzyme. Despite consuming dietary fructose, they excrete sugar in their urine. Clinical observations in this population suggest a lack of increased risk for obesity or diabetes, supporting the role of KHK as a key bottleneck linking fructose exposure to energetic stress [15]. Fructose itself is not the primary toxicant; rather, this suggests that KHK-mediated flux is a permissive requirement for fructose-driven ATP depletion and its subsequent metabolic sequelae.

2.3. Pharmacological Validation: Clinical KHK Inhibition

The causal role of KHK in driving metabolic pathology is further supported by recent Phase 2 clinical trials involving selective KHK inhibitors (e.g., PF-06835919 and LY3522348). In patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, pharmacological inhibition of KHK resulted in significant reductions in liver fat content and improved markers of insulin sensitivity [16][17].

2.4. Decision-Making Under Energy Constraint

We applied the principles of Intracellular Energy Variability to explain the transition from health to fragility [18]. In high-voltage cells, there is an "energy surplus" that permits the cell to choose repair and renewal processes. However, once the KHK-mediated "sink" drops the ATP/ADP ratio below a critical threshold, driving a shift toward mitochondrial fission and reduced energetic flexibility (see Fig. 2), the cell loses the capacity for phenotypic choice [19]. It becomes metabolically anchored in a defensive state and is unable to generate the energy required to exit the Cell Danger Response [5].

3. The Mechanics of the Energetic Trap

Tissue-Specific Vulnerability. Although the energetic principles described here are conserved across cell types, tissues differ markedly in their buffering capacity, mitochondrial reserves, and tolerance to energetic variability. Organs such as the liver, kidney, vascular endothelium, and hypothalamus are likely to represent early fail points due to high metabolic throughput, limited redundancy, or tight coupling between energy status and systemic regulation [6]. These differences may help explain the heterogeneous clinical presentation of chronic diseases, even when driven by shared upstream energetic constraints.

3.1. The Mandatory ATP Drain: Stoichiometric Irreversibility

The divergence between glucose and fructose is fundamentally a failure of enzymatic regulation. In the glucose pathway, Phosphofructokinase-1 (PFK-1) acts as a highly regulated “safety valve.” PFK-1 is tightly regulated by ATP, citrate, and other allosteric signals that physically throttle glucose flux to prevent an ‘energetic surge’ [20].

In contrast, ketohexokinase isoform C (KHK-C) is an unregulated metabolic sink. KHK-C does not exhibit allosteric feedback inhibition by its products or ATP [21]. Its Vmax is significantly higher than that of glucokinase, meaning that it can phosphorylate fructose at a rate that far outpaces the cell’s ability to regenerate its adenine nucleotide pool [14].

This creates a potent stoichiometric drain for the reaction. For each molecule of fructose processed, a phosphate group is sequestered from the cytosolic ATP pool. While standard ATP-to-ADP conversion remains within a closed-loop recycling system, KHK-driven flux initiates open-loop degradation. By sequestering inorganic phosphate (Pi) into fructose-1-phosphate faster than it can be recycled—a process we characterize as a ″phosphate heist″—the resulting rise in the AMP:ATP ratio does not merely signal more fuel; it forces the entry of AMP into the catabolic pathway mediated by AMP Deaminase (AMPD) [22][23].

This results in the irreversible conversion of the adenine nucleotide pool into uric acid, physically contracting the cell’s energy substrate. This transition from a transient ″spending problem″ to a permanent structural adenylate deficit means that the cell is left with a shrunken pool of total nucleotides (the sum of ATP + ADP + AMP). Consequently, the cell becomes physically incapable of ″recycling″ its way back to homeostatic energy charge, even if the fructose flux ceases, as it no longer possesses the raw nucleotide materials required for restoration [24][25].

3.1.1. Mechanistic Clarification: Acute depletion vs adenylate pool contraction

To avoid ambiguity, we distinguish between two related but separable energetic phenomena:

1. **Acute ATP/Pi depletion.** Rapid fructose phosphorylation sequesters inorganic phosphate (Pi) and lowers ATP levels, increasing the AMP:ATP ratio. This component is rapid and, in principle, reversible once the flux ceases and the phosphate/ATP levels are restored [24][22].
2. **Adenylate pool contraction (structural deficits).** When elevated AMP is routed through AMP Deaminase (AMPD) and downstream purine degradation, adenine nucleotides are converted to

diffusible end-products (e.g., uric acid) that may be exported or further metabolized [25]. Under sufficiently high or repeated flux, this can reduce the *total adenylate pool* (ATP + ADP + AMP), shifting the cell from a transient energy signal to a rebuilding problem, as restoring adenylates requires ATP-expensive salvage and/or de novo synthesis [3][14]. Crucially, while the KHK-mediated stoichiometric drain is active, the resulting low-voltage state creates a 'kinetic lock' on the purine salvage pathway; the cell lacks the requisite ATP to reassemble the nucleotide building blocks it is actively shedding as uric acid [24][22][23].

In this study, “open-loop degradation” refers specifically to (2): a net loss of adenylate equivalents from the recyclable pool, creating an energetic recovery barrier that is not resolved by substrate availability alone [22][23].



Figure 1. ***The KHK-AMPD Stoichiometric Sink and Adenylate Pool Contraction.*** *Schematic representation of the transition from homeostatic adenylate recycling to open-loop degradation.* ***(Left) Homeostasis:*** *Inorganic phosphate (Pi) and ADP are recycled into ATP via mitochondrial oxidative phosphorylation, maintaining a stable "adenylate currency."* ***(Right) Sink:*** *KHK-mediated phosphorylation acts as an unregulated funnel that receives both dietary and endogenous fructose. Endogenous production is triggered by diverse stressors, including hyperglycemia, high osmolality, alcohol, hypoxia, and ischemia*[7][8]*. This flux sequesters Pi into a metabolic vault (Fructose-1-Phosphate). This "phosphate heist" precipitates a collapse in the ATP:AMP ratio, diverting AMP (The Dead Battery) into the AMP Deaminase (AMPD) shredder. The result is the irreversible loss of adenine nucleotides to Uric Acid, physically contracting the total adenylate pool and creating a state of structural debt that stops simple caloric recycling*[22][23]*.*

3.2. The Cerebral Fructose Factory (The BBB Paradox)

While the Blood-Brain Barrier (BBB) exhibits low expression of the fructose transporter GLUT5, the central nervous system is not immune to fructose-mediated energy failure. Recent 13C NMR spectroscopy has confirmed that the human brain possesses the machinery to synthesize fructose via the polyol pathway [8]. In the presence of hyperglycemia or when triggered by osmotic stressors such as alcohol or dietary salt, Aldose Reductase (AR) converts glucose to sorbitol, which is then oxidized to fructose by Sorbitol Dehydrogenase (SDH) [13].

The Blood-Brain Barrier does not require insulin for glucose uptake, as it primarily utilizes the GLUT1 transporter for endothelial crossing and GLUT3 for neuronal uptake [26][27]. Consequently, systemic hyperglycemia directly leads to a proportional increase in cerebral glucose concentrations [28]. We hypothesize that these glucose surges act as the mandatory substrate for the hypothalamic polyol pathway, creating localized pulses of endogenous fructose that trigger the Endocrine Triage described in Section 4.3 [3][8].

Once produced in the hypothalamus and hippocampus, cerebral KHK metabolizes this 'Invisible Fructose.' Unlike the liver, where KHK-C dominates, the brain primarily expresses KHK-A [29]. While KHK-A exhibits a significantly lower affinity (Km) for fructose than the hepatic C-isoform, its strategic localization within the brain's metabolic sensing nodes allows even low-level polyol flux to induce a localized energetic deficit [3]. This 'Intracellular Starvation' occurs specifically in the neurons responsible for systemic regulation, forcing a transition from renewal to a survival-driven foraging state.

Crucially, this endogenous conversion is not limited to the chronic state of diabetes. We hypothesize that transient hyperglycemia may increase polyol pathway flux in susceptible tissues, generating localized pulses of endogenous fructose sufficient to perturb ATP homeostasis in energy-sensitive regions such as the hypothalamus and vascular endothelium. Whether typical postprandial excursions in normoglycemic humans generate sufficient KHK-dependent ATP depletion to meaningfully impair hypothalamic energy sensing remains an open empirical question and represents a critical test of this framework.

3.3. The Fragile Phenotype: Mitochondrial Structural Breakdown

The persistence of fragility is not merely chemical; it is structural. The transition to this "Fragile Phenotype" is mediated by the uric acid-dependent inhibition of mitochondrial aconitase [30]. This creates a **metabolic 'dam'** within the Krebs cycle; when aconitase is inhibited, citrate can no longer be processed for energy and instead accumulates, leaking into the cytoplasm.

Once in the cytosol, this exported citrate acts as a potent signaling molecule that activates lipogenic programs (via Acetyl-CoA carboxylase). This explains the paradox of ectopic fat storage: the cell drives lipogenesis and fat accumulation even when whole-organism energy balance is negative, simply because the citrate "dam" has rerouted the fuel lines [31].

This state of "Energetic Congestion"—where fuel is present but cannot be processed—serves as the primary stimulus for mitochondrial fission. The high-fructose flux suppresses Mitofusin-2 (Mfn2) and stimulates Dynamin-related protein 1 (Drp1), leading to the physical fragmentation of the mitochondrial network [32]. This fission results in a loss of cristae density and a drastic reduction in the efficiency of the electron transport chain [33]. This structural shift from a fused network to fragmented defense units is visualized in Figure 2.



Figure 2. ***Mitochondrial Morphological Transition as a Feature of the Cell Danger Response. (Left) Metabolic Efficiency:*** *Under homeostatic conditions, Mitofusin-2 (Mfn2) maintains a fused, tubular network that optimizes ATP synthesis and resource sharing* [18][19]. ***(Center) The Catalyst:*** *Elevated intracellular Uric Acid (generated in Figure 1) inhibits Aconitase, stalling the Krebs cycle and signaling an environmental threat* [25][34]. ***(Right) Cellular Defense:****This signal triggers Drp1-mediated fission, breaking the network into isolated, low-voltage fragments* [33][32]. *While this compartmentalization protects the cell from systemic failure, it induces energetic hysteresis, locking the system into a survival-over-growth state—a hallmark of the Cell Danger Response* [1][5].

The cell is now in a state of “Bio-energetic Rigidity.” It is physically locked in a low-efficiency state that resists standard caloric restriction. In this state, the cell cannot effectively oxidize fat because its mitochondria are fragmented and "unplugged." Crucially, the cell faces a significant kinetic barrier to recovery: the process of mitochondrial re-fusion is itself an ATP-dependent "luxury" program. A compromised cell, anchored by its "structural debt," may struggle to meet the energetic threshold required to fuse its mitochondria back into a functional network [5][35].

3.4. The Secondary Sink: The NAD+/BH4 Descent

The KHK-mediated ATP drain does not merely starve the cell of fuel; it initiates a secondary "vacuum" of essential repair co-factors. The rapid generation of intracellular uric acid acts as a pro-oxidant stimulus, activating the NF-κB signaling pathway and increasing the expression of inflammatory cytokines, specifically TNF-α [36]. This inflammatory milieu induces the expression of CD38, a membrane-bound enzyme and a major consumer of Nicotinamide Adenine Dinucleotide (NAD+) [37].

As CD38 activity increases, the cellular NAD+ pool—mandatory for DNA repair via PARPs and metabolic regulation via Sirtuins—is rapidly depleted [38]. Simultaneously, the oxidative stress generated by this cascade "burns up" the cellular supply of Tetrahydrobiopterin (BH4). BH4 is the essential co-factor for both neurotransmitter synthesis (Dopamine/Serotonin) and the maintenance of vascular health [39]. When BH4 is depleted, Endothelial Nitric Oxide Synthase (eNOS) becomes "uncoupled": instead of producing Nitric Oxide (NO) to relax blood vessels, the enzyme begins producing Superoxide ($O_2^{\cdot-}$), further accelerating oxidative damage and inducing the vascular rigidity characteristic of chronic metabolic disease [40].

3.5. The Paracrine Bridge: A Hypothesis of Contagious Fragility

Building on the observation that stressed cells release Extracellular Vesicles (EVs) and "alarmins" (e.g., HMGB1), we propose a second-order hypothesis where KHK-driven energetic depletion initiates a paracrine relay of energy failure. In this "Contagious Fragility" model, the stressed cell recruits neighboring macrophages into a high-CD38, pro-inflammatory state, effectively exporting NAD+ depletion across the tissue infrastructure [38][41].

Consequently, metabolic disease may be viewed not as a series of isolated cellular failures, but as a form of "Contagious Fragility," wherein the autophagic secretome [42] and paracrine propagation of energetic stress allow a localized leak to erode organ-level resilience.

3.6. The Polyol Feedback Loop: The Self-Loading Trap

Finally, the model must explain the trap's persistence. Uric acid does not merely consume co-factors; it acts as a feed-forward signal that upregulates the expression of KHK itself [23]. This creates a “Self-Loading Trap”: once a cell enters the CDR due to an initial stressor (such as hyperglycemia or high-salt intake), the resulting uric acid ensures that the cell remains hypersensitive to any subsequent fructose flux, whether dietary or endogenous. This explains the clinical observation of “Metabolic Memory,” where the energetic “brownout” persists long after the initial dietary insult has been removed.

In this state of bio-energetic rigidity, the cell's ability to discriminate between endogenous and exogenous purine flux is compromised. We hypothesize that as long as KHK flux keeps the ATP:AMP ratio depressed, any additional purine building blocks—whether from turnover or diet—are more likely to be diverted through the AMPD 'shredder' into uric acid rather than being salvaged for repair, effectively turning the structural debt into a self-stabilizing energetic barrier [3][25][23][35].

3.7. Hyperglycemia as a Volume Driver of Endogenous Flux

While osmotic stressors (salt, alcohol) act as potent activators of Aldose Reductase (AR), hyperglycemia serves as the primary substrate driver for high-volume polyol flux. Under normoglycemic conditions, AR exhibits a high Km for glucose, resulting in minimal conversion. However, in states of persistent or spike-driven hyperglycemia, the saturation of the glycolytic pathway (Hexokinase/Glucokinase) forces a metabolic overflow into the polyol-fructose axis [7][8].

This "Glucose-to-Fructose Shunt" represents a catastrophic bypass of cellular energy regulation. Unlike glucose, which is throttled by Phosphofructokinase-1 (PFK-1), the resulting endogenous fructose is immediately phosphorylated by KHK, initiating the stoichiometric ATP drain described in Section 3.1. We propose that in the modern metabolic environment, hyperglycemia functions not merely as a marker of insulin resistance, but as a feed-forward raw material that sustains the KHK-mediated energetic trap, even in the absence of dietary fructose. This explains the "Metabolic Memory" observed in diabetic complications, where energetic failure persists despite the subsequent normalization of blood glucose [23].

3.8. Confidence Tiers and Mechanistic Probability

We emphasize that while the individual biochemical nodes described in this framework are supported by established experimental evidence, the integrated multi-step propagation model should be regarded as a testable systems-level hypothesis rather than a fully validated pathway. To clarify the current state of evidence, we categorize the components of the KHK–Polyol axis into four tiers of confidence:

1. **Established:** The role of KHK in rapid ATP/Pi depletion, the induction of AMP Deaminase, and the subsequent generation of intracellular uric acid [22][25][23].
2. **Strongly Supported:** The inhibition of mitochondrial aconitase by uric acid and the resulting shift toward a Drp1-mediated fission phenotype [30][34][33][32].
3. **Hypothesized:** The role of systemic stress and hyperglycemia in driving hypothalamic polyol flux and the subsequent "Endocrine Triage" of the reproductive axis [8][9][43][44].
4. **Speculative but Testable:** The "Contagious Fragility" model, wherein KHK-driven energetic stress initiates paracrine propagation of NAD+ depletion via EV-mediated CD38 activation [45][38][41].

By delineating these tiers, we aim to provide a roadmap for focused experimental validation while maintaining a rigorous distinction between observed biochemical events and the broader physiological cascade we propose.

4. Discussion—The Hierarchy of Metabolic Models

4.1. Resolving the Caloric and Hormonal Gaps

For decades, metabolic science has been divided into two camps: the Calories In, Calories Out (CICO) model and the Carbohydrate-Insulin Model. While both offer clinical utility, they describe symptoms rather than the source [46].

Our model proposes that Intracellular Starvation is a plausible upstream driver that can unify both. Table 1 provides a detailed comparison of how this energetic framework resolves specific gaps in existing caloric and hormonal models. When the KHK-mediated stoichiometric sink depletes ATP, the cell is no longer “full,” regardless of the blood glucose level. This creates a state of hypometabolism: the organism eats (Hyperphagia) because the cell cannot meet the “minimum voltage” required for basic maintenance [47]. Similarly, Insulin Resistance is reframed not as a primary pathology, but as a secondary “Circuit Breaker” [46]. In a cell where mitochondria are physically fragmented (fission) and the TCA cycle is stalled (aconitase inhibition), the cell must refuse further fuel to prevent a catastrophic surge of reactive oxygen species (ROS) [32]. A plausible interpretation is that Insulin Resistance may represent an initially protective ‘circuit breaker’ to prevent ROS overload in an already compromised engine, though its chronic persistence ultimately becomes maladaptive [46].

The systemic propagation of cellular fragility is further substantiated by recent evidence identifying p62-dependent secretory autophagy as a critical pathway for the unconventional exocytosis of proteotoxic cargo. Specifically, the Alzheimer-associated ubiquitin variant UBB+1 has been shown to be diverted toward secretory vesicles when degradative pathways are impaired [42]. This suggests that when local degradative capacity is exhausted—a state potentially precipitated by the energetic constraints of the KHK-mediated stoichiometric sink—the cell may prioritize the export of pathological markers over internal sequestration. This mechanism facilitates a 'contagious' spread of metabolic dysfunction across the vascular relay, transforming localized energetic failure into a systemic driver of chronic disease persistence.

doi.org/10.32388/R2NFG9

Framework	Primary focus	Strengths	Key limitation	Energetic interpretation	Distinct, testable predictions
Caloric balance (CICO)	Energy intake vs expenditure	Describes population-level weight trends	Does not specify why appetite and energy conservation persist despite apparent fuel availability	Persistent hyperphagia [47] and reduced expenditure [12] are reframed as downstream responses to an intracellular energetic deficit.	In metabolically stressed tissue, ATP:ADP and ΔG-ATP remain depressed despite caloric availability; improvements in ΔG-ATP precede spontaneous intake reduction.
Carbohydrate–insulin models	Insulin signaling and fuel partitioning	Explains lipid storage dynamics and glycemic control	Often treats insulin resistance as primary pathology rather than a secondary constraint	Insulin resistance is modeled as a protective "circuit breaker" to limit ROS in energetically constrained mitochondria [32][46][48].	KHK modulation improves ΔG-ATP and mitochondrial morphology even when insulin signaling changes are modest.
Lipotoxicity-First	Ectopic lipid and lipid intermediates	Links lipid overload to organ dysfunction	Ambiguous directionality between lipid accumulation and mitochondrial dysfunction	Ectopic lipid storage is a downstream consequence of TCA congestion and citrate export under energetic constraint [25][31].	Restoration of mitochondrial network integrity (fusion/cristae density) precedes reductions in ectopic lipid in KHK-inhibited conditions.
Inflammation-First	Cytokines and immune activation	Explains fibrosis and tissue injury patterns	Often circular on causality, limited upstream trigger specificity	Energetic depletion acts as the upstream trigger, coupling metabolic stress to CD38-	CD38 activity and NAD+ decline correlate with energetic depletion markers and are

Framework	Primary focus	Strengths	Key limitation	Energetic interpretation	Distinct, testable predictions
				mediated NAD+ loss [49] [36][38].	rescued by KHK inhibition in fructose-permissive states.
Mitochondrial dysfunction models	ETC inefficiency, ROS, aging phenotypes	Aligns with multi-system symptoms	Often lacks a common upstream driver that is modifiable	KHK flux is proposed as a modifiable upstream sink that biases fission and reduces energetic flexibility [19][34][33].	In fructose-permissive conditions, KHK inhibition increases Pi availability, improves ATP:ADP, reduces Drp1 activation, and increases Mfn2/OPA1 [32].
Cell Danger Response (CDR)	Defensive metabolic states and phase transitions	Explains persistence and non-linear recovery	Does not specify a dominant biochemical stabilizer in common metabolic disease	KHK-mediated energetic loss is proposed as a primary biochemical stabilizer that maintains CDR-like phenotypes [1][18][23].	Relief of KHK flux shifts multiple CDR-linked readouts (ΔG-ATP, NAD+, mitochondrial morphology) in a coordinated fashion.

Table 1. Comparative Analysis of Metabolic Frameworks. A heuristic comparison to illustrate how the proposed framework re-interprets observations explained by other metabolic models. This table delineates how the proposed Unified Bio-energetic Model (the KHK–Polyol Axis) provides a convergent energetic context for the mechanistic observations found in traditional caloric, hormonal, and inflammatory models of chronic disease.

Note: *Predictions are framed as measurable examples, not exhaustive endpoints. The model is intended to be tested with selective KHK and CD38 perturbations and direct energetic readouts.*

4.2. The Tipping Point as a Decision Switch

A critical question in chronic disease is why some systems recover while others spiral into persistence. We propose that effective cellular energy charge functions as a biophysical switch that governs whether a cell can exit defensive programs and re-enter repair. When energy charge remains above a tissue-specific threshold, cells retain the capacity to transition from CDR2-associated programs toward differentiation and renewal (CDR3) [5].

In fructose-permissive states, unregulated KHK flux can keep energy charge chronically depressed, preventing the threshold conditions required for repair. The system becomes metabolically anchored: defensive programs persist not because the instigator is still present, but because the energetic requirements for reversal are unmet [5]. This defines the tipping point, the moment when cumulative energetic deficit converts a reversible stress response into a self-stabilizing state of non-recovery.

4.2.1. Clinical Latency and the Depth of the Energetic Well

A critical corollary of the hysteresis model is the prediction of clinical latency. We propose that the duration required for observable phenotypic recovery is proportional to the "depth" of the energetic well—defined by the cumulative duration of CDR2-anchoring and the resulting structural debt, such as the degree of mitochondrial fragmentation and NAD+ depletion [5][35]. While sealing the KHK leak provides an immediate cessation of the stoichiometric drain, the system cannot achieve a "Voltage Spike" until the intracellular phosphate and NAD+ pools are sufficiently replenished to pay off this metabolic debt [19]. Consequently, younger or less metabolically compromised individuals may cross the repair threshold within days, whereas chronically compromised systems may require a sustained energetic surplus (a "Voltage Spike") for weeks or months before the ATP-dependent processes of mitochondrial re-fusion and proteostasis can manifest as systemic improvement [32].

This threshold represents a neuro-metabolic tipping point; we hypothesize that the subjective resolution of hyperphagia (cravings) and lethargy (perceived energy) coincides with the restoration of hypothalamic energy charge and the subsequent deactivation of survival-driven foraging programs [9][44]. In this view, 'willpower' is not a psychological resource to be summoned, but a physiological byproduct of a high-voltage energetic state.

4.3. Endocrine Triage: The Hypothalamic Fail-Point

A significant systemic implication of this model concerns the brain's 'Endocrine Triage' [50]. Kisspeptin neurons in the hypothalamus act as the primary metabolic gatekeepers for the reproductive axis; they are hyper-sensitive to energetic variability, requiring a specific ATP threshold to pulsate and signal the release of GnRH [44]. We propose that the metabolic sink created by endogenous fructose production within these neurons serves as a plausible "fail-point" for reproductive and motivational drive.

This systemic triage is characterized by a high degree of regional specificity rather than a global energetic collapse. The 'brownout' selectively targets modules that would impede a survival-driven foraging state, such as higher-order cognitive processing and reproductive signaling [44]. Conversely, sensory systems essential for immediate survival and foraging success, such as the primary visual cortex, remain metabolically protected [9]. This pattern reflects a targeted redistribution of energetic resources in which regions supporting long-term planning and reproduction are downregulated, while circuits essential for immediate environmental interaction are preserved.

When the localized KHK-mediated ATP drain drops cellular voltage below a critical threshold in these sensing nodes, the brain is forced to abort "luxury" programs to prioritize core survival. While the precise manifestations of this triage exhibit sexual dimorphism—typically presenting as an earlier cessation of reproductive signaling in females and a more pronounced disruption of dopamine-driven motivation in males—the underlying bio-energetic fail-point remains consistent [44]. The system is not "broken"; it is executing a survival-driven ejection of high-energy modules (libido, motivation, fertility) in response to a perceived hypothalamic energy void.

4.3.1. The Systemic Energetic Cascade

Figure 3 illustrates the spatial progression of this failure. The process initiates at the Enteric/Hepatic Sink, where KHK-mediated phosphorylation induces adenine nucleotide contraction [7][22][25]. These stressors, alongside exported EVs and proteotoxic cargo [42], activate the Vascular Relay, inducing systemic CD38 expression and NAD+ depletion [45][38]. This pressure converges on the Central Integration nodes of the hypothalamus, where localized polyol flux drives a "brownout" that necessitates the Endocrine Triage of reproductive and motivational axes [8][44][51].



Figure 3. ***The Systemic Energetic Cascade – From Absorption to Endocrine Triage.*** *This schematic maps the multi-organ progression of energetic failure.* **(1)** ***Enteric Absorption & Local Sink:*** *Initial phosphorylation of dietary and endogenous fructose within gut enterocytes* [7][52][53]. **(2)** ***Hepatic Stoichiometric Drain:*** *The primary energetic sink where unregulated KHK-C activity in liver hepatocytes depletes cellular adenine nucleotides* [22][23]. **(3)** ***Vascular Relay:*** *Circulating uric acid, extracellular vesicles (EVs), and autophagic secretome* [42] *propagate "Contagious Fragility" in vascular endothelial cells, exporting localized proteostatic failure across the system's infrastructure* [38][41][42]. **(4)** ***Hypothalamic Triage:*** *Hyperglycemia and stress activate the cerebral polyol pathway, affecting hypothalamic sensing nodes which execute survival-driven programs over reproductive and motivational drive* [8][44][51].

4.4. The Cost of Precision

Oxidative phosphorylation maintains homeostasis within narrow thermodynamic margins. In such a system, modest shifts in effective energy charge can have outsized consequences, not because the change is dramatic, but because many repair functions are threshold-dependent (proteostasis, mitochondrial dynamics, ion homeostasis, and redox buffering) [54]. This helps explain why chronic low-grade fructose-permissive conditions, a slow drip of dietary fructose and/or polyol activation, may generate progressive dysfunction over time.

5. Integration—Sealing the Leak to Restore Resilience

5.1. The Restriction Fallacy and the GLP-1 Paradox

Standard clinical approaches to metabolic disease focus on removing the instigator—restricting dietary calories or refined sugars. While necessary, our model explains why such measures often fail to “reset” the system. Once the Mitochondrial Morphological Shift (fission) has occurred [32] and the Polyol Feedback Loop is established [7], the cell is locked in a low-voltage cycle that is no longer dependent on exogenous intake.

This “top-down” restriction is currently exemplified by the use of GLP-1 receptor agonists (GLP-1RAs). While these medications are highly effective at muting hypothalamic hunger and improving systemic glycemia, they do not directly address the intracellular stoichiometric sink. Because GLP-1RAs do not seal the KHK energetic leak or repair fragmented mitochondria, the underlying state of Intracellular Starvation persists [47]. This may provide a mechanistic basis for why discontinuation is frequently followed by weight regain; without addressing the underlying energetic sink, the system remains in a state of "Intracellular Starvation," maintaining the survival-driven appetite signaling that characterizes the anchored Cell Danger Response [1][47].

5.2. Experimental Modulation of the KHK–CD38 Axis

The present framework is agnostic to the specific agent used to modulate the proposed energetic bottleneck. Conceptually, intervention strategies fall into two broad classes: (i) reducing KHK-mediated fructose flux (thereby sealing the stoichiometric ATP/Pi sink) and (ii) preserving NAD+ and redox repair capacity by attenuating CD38-linked NAD^+ consumption and inflammatory induction.

KHK-directed strategies include selective pharmacological KHK inhibitors currently in clinical development (e.g., PF-06835919 and LY3522348), which have demonstrated reductions in liver fat content and improvements in insulin sensitivity in Phase 2 clinical settings [16][17]. Additional upstream strategies that may reduce KHK substrate delivery include dietary fructose restriction [53] and approaches aimed at limiting endogenous fructose generation via the polyol pathway, such as modulation of aldose reductase activity or mitigation of the osmotic and hyperglycemic triggers that drive polyol flux [7][8].

CD38/NAD+-directed strategies include selective CD38 inhibition and related approaches that reduce NF-κB–linked inflammatory induction of CD38 or preserve NAD+-dependent repair capacity. These interventions are mechanistically separable from KHK inhibition and provide an orthogonal means of testing whether NAD+ depletion functions as a secondary stabilizer of energetic non-recovery [37][38].

Within this broader intervention space, the flavonoid luteolin serves as a useful illustrative example because it has been reported in preclinical systems to inhibit KHK-mediated fructose phosphorylation [55] and CD38-dependent NAD+ consumption [56], while also attenuating NF-κB–linked inflammatory signaling [57]. Like many flavonoids, luteolin has limited and variable oral bioavailability; therefore, translation would require confirmation of systemic exposure and target engagement rather than assuming dietary intake produces meaningful KHK/CD38 modulation in vivo. While luteolin is only one example among several candidate intervention classes, its reported dual activity provides a practical window into the hypothesis that partial, simultaneous relief of KHK flux and CD38-linked NAD+ depletion may yield coordinated, multi-system energetic recovery rather than pathway-isolated effects [58].

Definitive validation of the framework will require orthogonal testing using selective KHK inhibition, selective CD38 inhibition, and direct measurement of intracellular energetic recovery, including ATP:ADP ratios, ΔG-ATP, NAD+ pools, and mitochondrial network dynamics.

5.3. Testable Predictions: Energetic hysteresis and a heuristic recovery range

We propose that recovery from the KHK-mediated trap exhibits energetic hysteresis: the path back to repair is not the simple reverse of the path into defense. Once mitochondrial fission and feedback signaling are established, removal of the exogenous instigator may be insufficient to reset cellular state [18]. We predict that re-engagement of ATP-dependent repair programs (including mitochondrial re-fusion) requires a threshold-like improvement in effective energy charge (ΔG-ATP and ATP:ADP), but the magnitude of this requirement is likely tissue- and context-dependent [5].

As a heuristic experimental target, we propose that a ~10–20% increase in ΔG-ATP (relative to the anchored CDR state) will fall within the regime where re-fusion dynamics (Mfn2/OPA1 engagement, cristae recovery) become kinetically favorable [32]. This range is not presented as a constant, but as a falsifiable starting point to be refined through “voltage titration” experiments described in Section 5.6.

5.3.1. The Thermodynamic Landscape of Persistence

Figure 4 utilizes a potential energy landscape to model the transition between cellular resilience and chronic fragility. This heuristic framework illustrates the non-linear nature of metabolic recovery. The **High-Voltage Plateau (Top Right)** represents the homeostatic repair state, where high ΔG-ATP and fused mitochondrial networks permit robust housekeeping and renewal [19][32][54].

Transitioning from this state, the **KHK-Mediated Sink** is visualized as a steep descent into the **Low-Voltage Basin (Bottom Left)**. This "Persistent Defense" state (CDR2) is characterized by bio-energetic rigidity [1][5]. Because the descent involves the physical contraction of the total adenine nucleotide pool—a "structural debt"—recovery is not a simple ascent [22][25]. The system faces an **Energetic Hysteresis Activation Barrier**; re-entry into the repair state requires a threshold-crossing **Restoration of ΔG-ATP and Purine Pool**. This "Voltage Spike" is necessary to provide the energetic surplus required to pay off the structural debt and re-initiate the ATP-expensive processes of purine salvage and mitochondrial re-fusion [5][18][35].

doi.org/10.32388/R2NFG9



Figure 4. ***Thermodynamic Landscape of Energetic Hysteresis and Salugenesis.*** *The cellular state is modeled as a transition between potential energy levels. These features are conceptual abstractions intended to illustrate energetic hysteresis rather than literal physical landscapes.* ***(Top Right) High-Voltage Plateau:*** *A state of homeostatic repair characterized by high ΔG-ATP* [54]*, fused mitochondrial networks* [32]*, and a complete adenine nucleotide pool* [22]*.* ***(The Precipice) The KHK-Mediated Sink:*** *Unregulated fructose phosphorylation acts as an open-loop metabolic drain, causing a rapid, non-allosteric loss of potential energy and adenine nucleotides* [21][24][23]*.* ***(Bottom Left) Low-Voltage Basin:*** *The system becomes anchored in a persistent Cell Danger Response (CDR2)* [1]*, where bio-energetic rigidity prevents spontaneous recovery.* ***(The Ascent) The Restoration Spike:*** *Due to energetic hysteresis and the "structural debt" of purine loss* [22][25]*, recovery is not a spontaneous reversal; re-entry into the repair state requires a threshold-crossing "Voltage Spike" in cellular energy charge to facilitate mitochondrial re-fusion and re-entry into the healing cycle* [5][18][19][35]*.*

5.4. Falsifiable Predictions

These predictions provide a roadmap for the experimental validation of the Unified Bio-energetic Model:

- **Causal Necessity of the KHK Funnel:** In KHK-deficient models (e.g., KHK-knockout mice or Essential Fructosuria human phenotypes), non-sugar stressors such as high salt intake, alcohol, or transient hyperglycemia will fail to induce mandatory ATP depletion or systemic metabolic syndrome [14].
- **Stoichiometric Restoration:** Selective KHK inhibition will increase the ATP:ADP ratio and ΔG-ATP in the liver, brain, and vascular endothelium under fructose-permissive conditions, independent of caloric intake or insulin signaling [53].
- **Mitochondrial Structural Reset:** KHK inhibition will reduce Drp1 activation and increase Mfn2/OPA1 expression, accompanied by a measurable shift toward fused mitochondrial networks [33].
- **CD38 and NAD+ Preservation:** CD38 inhibition will reduce CD38 activity, preserve NAD+ pools, and restore NAD+-dependent signaling (e.g., SIRT activity) in metabolically stressed tissues [38].
- **Paracrine Signal Interruption:** Potent KHK inhibition in "source" tissues (e.g., hepatocytes) will attenuate the release of pro-inflammatory Extracellular Vesicles (EVs) and "alarmins" like HMGB1, preventing the recruitment of CD38+ macrophages and preserving NAD+ pools in neighboring healthy tissues [41].
- **Synergistic Recovery:** Combined KHK and CD38 inhibition will produce supra-additive improvements in ΔG-ATP and mitochondrial network integrity, exceeding the summed effects of either intervention alone.
- **Reversal of Endocrine Triage:** Restoration of the hypothalamic energy charge via cerebral KHK modulation will restore Kisspeptin pulsatility and Dopamine-driven motivation [44].

5.5. Proposed Experimental Validations

These experiments are designed to test the limits of the framework and distinguish it from purely caloric or hormonal models:

- **The Paracrine Relay Study:** Utilizing a microfluidic co-culture system to demonstrate that KHK-driven energetic stress in hepatocytes induces CD38-mediated NAD+ depletion in adjacent healthy vascular endothelial cells via exosomal transfer.
- **The "Voltage Spike" Titration:** Using live-cell imaging to identify the exact ΔG-ATP threshold (the heuristic recovery band) required to trigger mitochondrial re-fusion (Mfn2 re-engagement) in cells previously anchored in the Cell Danger Response.

- **The GLP-1 Paradox Head-to-Head:** Comparing a GLP-1RA-only cohort against a GLP-1RA + KHK-inhibitor (e.g., LY3522348) cohort. We predict that while both will lose weight, only the combined cohort will show a restoration of mitochondrial cristae density and a "reset" of hypothalamic satiety markers, preventing post-treatment weight regain.

6. Conclusion—A Narrative of Restoration

6.1. Summary: The Failure of Resilience

Chronic disease is fundamentally a failure of cellular resilience, not a simple surplus of calories. By identifying the KHK-mediated energetic trap as a dominant biophysical amplifier, we move toward a cohesive understanding of how disparate metabolic stressors converge into a singular state of human fragility [3]. We demonstrate that whether the initiating stressor is dietary sugar, high salt, alcohol, or transient hyperglycemic spikes, the physiological result converges on a singular biophysical event: a mandatory, unregulated drain on cellular voltage [10]. This stoichiometric leak—driven by the metabolism of fructose—traps the cell in a persistent Cell Danger Response (CDR), where repair is sacrificed for defense, and systemic health begins its slow decay [5].

6.2. Reframing the Goal: From Restriction to Restoration

Modern metabolic medicine has largely focused on “top-down” interventions—restricting fuel or muting appetite signaling. While these strategies can slow the progression of disease, they do not inherently restore the cell’s capacity for high-voltage operation once the Structural Deficit (purine loss) and the Structural Lock (mitochondrial fission) have taken hold [23]. Our model proposes a transition from Defense to Restoration. Resolving the KHK-mediated energetic trap is a rate-limiting prerequisite for restoring the biological capacity for health. Only by sealing this “leaky battery”, replenishing the depleted phosphate and adenine pools, and providing the "Voltage Spike" required for mitochondrial re-fusion can the system return to a state of renewal. [1].

6.3. Limitations and Falsifiability

This model proposes KHK-dependent fructose metabolism as a high-leverage energetic amplifier of disease persistence, not the sole cause of all pathology. Primary mitochondrial disorders, hypoxia-driven injury, and acute inflammatory states may produce energetic failure through KHK-independent

doi.org/10.32388/R2NFG9

mechanisms. Key falsifiable predictions include tissue-level energetic biomarker shifts independent of caloric restriction [16] and CD38-mediated paracrine interruption [38].

Final Statement

Ultimately, a shared signature across diverse chronic pathologies is one of systemic energetic depletion. We identify the unregulated metabolism of fructose—whether ingested or endogenously produced—as a major, testable biophysical amplifier of this failure. By reframing metabolic syndrome as a KHK-mediated energetic trap, we move beyond the limitations of caloric and hormonal models. Resolving this trap may represent a rate-limiting requirement for restoring biological resilience in a substantial subset of chronic metabolic states. When cellular voltage is restored, the body's innate capacity for resilience is re-engaged, and the "Forest" of chronic decay can finally begin the process of systemic regeneration.

Further research is required to validate these stoichiometric thresholds and to determine if pharmacological 'sealing' of the KHK leak can indeed restore the biological capacity for health in human populations [59].

Statements and Declarations

Funding

No specific funding was received for this work.

Potential Competing Interests

C.R.M. and P.A.G. are co-founders of LIV3 Health, which develops nutritional protocols and dietary supplements. The conceptual basis for these interventions is derived from the established biochemical research on the KHK–Polyol axis cited in this manuscript.

Ethics

Not applicable. This study is a theoretical review and did not involve human participants or animals.

Data Availability

No new data were generated or analyzed in this study. All supporting evidence is derived from the cited literature.

Author Contributions

C.R.M. was responsible for the primary conceptualization, literature synthesis, and writing of the manuscript. P.A.G. provided clinical vetting, metabolic framework validation, and editorial review.

References

1. a, b, c, d, e, f, g, h, i *Naviaux RK (2014). "Metabolic Features of the Cell Danger Response." Mitochondrion.* ***16****:7–17. doi:10.1016/j.mito.2013.08.006.*
2. ^ *Wallace DC (2011). "Bioenergetic Origins of Complexity and Disease." Cold Spring Harbor Symposia on Quantitative Biology.* ***76****:1–16. doi:10.1101/sqb.2011.76.010462.*
3. a, b, c, d, e, f, g *Johnson RJ, Tolan DR, Bredesen D, Nagel M, Sánchez-Lozada LG, Fini M, Burtis S, Lanaspa MA, Perlmutter D (2023). "Could Alzheimer's Disease Be a Maladaptation of an Evolutionary Survival Pathway Mediated by Intracerebral Fructose and Uric Acid Metabolism?" Am J Clin Nutr.* ***117****(3):455–466. doi:10.1016/j.ajcnut.2023.01.002.*
4. ^ *Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, Gersch MS, Benner S, Sánchez-Lozada LG (2007). "Potential Role of Sugar (Fructose) in the Epidemic of Hypertension, Obesity and the Metabolic Syndrome, Diabetes, Kidney Disease, and Cardiovascular Disease." Am J Clin Nutr.* ***86****(4):899–906. doi:10.1093/ajcn/86.4.899.*
5. a, b, c, d, e, f, g, h, i, j, k, l *Naviaux RK (2023). "Mitochondrial and Metabolic Features of Salugenesis and the Healing Cycle." Mitochondrion.* ***70****:131–163. doi:10.1016/j.mito.2023.04.003.*
6. a, b *Moreno-Sánchez R, Marín-Hernández A, Gallardo-Pérez JC, Quezada H, Encalada R, Rodríguez-Enríquez S, Saavedra E (2012). "Phosphofructokinase Type 1 Kinetics, Isoform Expression, and Gene Polymorphisms in Cancer Cells." J Cell Biochem.* ***113****(5):1692–1703. doi:10.1002/jcb.24039.*
7. a, b, c, d, e, f, g, h *Lanaspa MA, Ishimoto T, Li N, Cicerchi C, Orlicky DJ, Ruzycki P, Rivard C, Inaba S, Roncal-Jimenez CA, Bales ES, Diggle CP, Asipu A, Petrash JM, Kosugi T, Maruyama S, Sanchez-Lozada LG, McManaman JL, Bonthron DT, Sautin YY, Johnson RJ (2013). "Endogenous Fructose Production and Metabolism in the Liver Contributes to the Development of Metabolic Syndrome." Nat Commun.* ***4****:2434. doi:10.1038/ncomms3434.*
8. a, b, c, d, e, f, g, h, i *Hwang JJ, Jiang L, Hamza M, Dai F, Belfort-DeAguiar R, Cline G, Rothman DL, Mason G, Sherwin RS (2017). "The Human Brain Produces Fructose from Glucose." JCI Insight.* ***2****(4):e90508. doi:10.1172/jci.insight.90508.*

9. a, b, c, d *Johnson RJ, Gomez-Pinilla F, Nagel M, Nakagawa T, Rodriguez-Iturbe B, Sanchez-Lozada LG, Tolan DR, Lanaspa MA (2020). "Cerebral Fructose Metabolism as a Potential Mechanism Driving Alzheimer's Disease." Front Aging Neurosci.* **12***:560865. doi:10.3389/fnagi.2020.560865.*
10. a, b *Lanaspa MA, Kuwabara M, Andres-Hernando A, Li N, Cicerchi C, Jensen T, Orlicky DJ, Roncal-Jimenez CA, Ishimoto T, Nakagawa T, Rodriguez-Iturbe B, MacLean PS, Johnson RJ (2018). "High Salt Intake Causes Leptin Resistance and Obesity in Mice by Stimulating Endogenous Fructose Production and Metabolism." Proc Natl Acad Sci U S A.* **115***(12):3138–3143. doi:10.1073/pnas.1713837115.*
11. ^ *Roncal Jimenez CA, Ishimoto T, Lanaspa MA, Rivard CJ, Nakagawa T, Ejaz AA, Cicerchi C, Inaba S, Le M, Miyazaki M, Glaser J, Correa-Rotter R, González MA, Aragón A, Wesseling C, Sánchez-Lozada LG, Johnson RJ (2014). "Fructokinase Activity Mediates Dehydration-Induced Renal Injury." Kidney Int.* **86***(2):294–302. doi:10.1038/ki.2013.492.*
12. a, b *Bairlein F (2002). "How to Get Fat: Nutritional Mechanisms of Seasonal Fat Accumulation in Migratory Songbirds." Naturwissenschaften.* **89***(1):1–10. doi:10.1007/s00114-001-0279-6.*
13. a, b *Andres-Hernando A, Johnson RJ, Lanaspa MA (2019). "Endogenous Fructose Production: What Do We Know and How Relevant Is It?" Curr Opin Clin Nutr Metab Care.* **22***(4):289–294. doi:10.1097/MCO.0000000000000573.*
14. a, b, c, d *Asipu A, Hayward BE, O'Reilly J, Bonthron DT (2003). "Properties of Normal and Mutant Recombinant Human Ketohexokinases and Implications for the Pathogenesis of Essential Fructosuria." Diabetes.* **52***(9):2426–2432. doi:10.2337/diabetes.52.9.2426.*
15. ^ *Johnston JA, Nelson DR, Bhatnagar P, Curtis SE, Chen Y, MacKrell JG (2021). "Prevalence and Cardiometabolic Correlates of Ketohexokinase Gene Variants Among UK Biobank Participants." PLoS ONE.* **16***(2):e0247683. doi:10.1371/journal.pone.0247683.*
16. a, b, c *Fukuda T, Thompson BR, Brouwers B, Qian HR, Wang W, Morse BL, LaBell ES, Durham TB, Konig M, Haupt A, Benson CT, MacKrell J (2025). "LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults." Diabetes Ther.* **16***(7):1399–1415. doi:10.1007/s13300-025-01752-5.*
17. a, b *Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Birnbaum MJ, Calle RA (2021). "Inhibition of Ketohexokinase in Adults With NAFLD Reduces Liver Fat and Inflammatory Markers: A Randomized Phase 2 Trial." Med.* **2***(7):800–813.e3. doi:10.1016/j.medj.2021.04.007.*
18. a, b, c, d, e, f *Kerr R, Jabbari S, Johnston IG (2019). "Intracellular Energy Variability Modulates Cellular Decision-Making Capacity." Sci Rep.* **9***(1):20196. doi:10.1038/s41598-019-56587-5.*

19. a, b, c, d, e, f*Maldonado EN, Lemasters JJ (2014). "ATP/ADP Ratio, the Missed Connection Between Mitochondria and the Warburg Effect." Mitochondrion.* ***19****(Pt A):78–84. doi:10.1016/j.mito.2014.09.002.*

20. ^*Sakakibara R, Uyeda K (1983). "Differences in the Allosteric Properties of Pure Low and High Phosphate Forms of Phosphofructokinase From Rat Liver." J Biol Chem.* ***258****(14):8656–62.*

21. a, b*Mayes PA (1993). "Intermediary Metabolism of Fructose." Am J Clin Nutr.* ***58****(5 Suppl):754S–765S. doi:10.1093/ajcn/58.5.754S.*

22. a, b, c, d, e, f, g, h, i, j, k*Van den Berghe G, Bronfman M, Vanneste R, Hers HG (1977). "The Mechanism of Adenosine Triphosphate Depletion in the Liver After a Load of Fructose. A Kinetic Study of Liver Adenylate Deaminase." Biochem J.* ***162****(3):601–9. doi:10.1042/bj1620601.*

23. a, b, c, d, e, f, g, h, i, j, k, l*Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, Hunter B, Andrés-Hernando A, Ishimoto T, Sánchez-Lozada LG, Thomas J, Hodges RS, Mant CT, Johnson RJ (2012). "Counteracting Roles of AMP Deaminase and AMP Kinase in the Development of Fatty Liver." PLoS ONE.* ***7****(11):e48801. doi:10.1371/journal.pone.0048801.*

24. a, b, c, d*Morris RC Jr, Nigon K, Reed EB (1978). "Evidence That the Severity of Depletion of Inorganic Phosphate Determines the Severity of the Disturbance of Adenine Nucleotide Metabolism in the Liver and Renal Cortex of the Fructose-Loaded Rat." J Clin Invest.* ***61****(1):209–220. doi:10.1172/JCI108920.*

25. a, b, c, d, e, f, g, h, i*Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006). "A Causal Role for Uric Acid in Fructose-Induced Metabolic Syndrome." Am J Physiol Renal Physiol.* ***290****(3):F625–F631. doi:10.1152/ajprenal.00140.2005.*

26. ^*McEwen BS, Reagan LP (2004). "Glucose Transporter Expression in the Central Nervous System: Relationship to Synaptic Function." Eur J Pharmacol.* ***490****(1-3):13–24. PMID 15094070. doi:10.1016/j.ejphar.2004.02.041.*

27. ^*Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, Vannucci SJ (2008). "The Facilitative Glucose Transporter GLUT3: 20 Years of Distinction." Am J Physiol Endocrinol Metab.* ***295****(2):E242–53. PMID 18577699. doi:10.1152/ajpendo.90388.2008.*

28. ^*Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Mason GF, Shulman GI, Shulman RG, Tamborlane WV (1992). "Direct Measurement of Brain Glucose Concentrations in Humans by 13C NMR Spectroscopy." Proc Natl Acad Sci U S A.* ***89****(3):1109–12. PMID 1736294. doi:10.1073/pnas.89.3.1109.*

29. ^*Page KA, Chan O, Arora J, Belfort-DeAguiar R, Dzuira J, Roehmholdt B, Cline GW, Naik S, Sinha R, Constable RT, Sherwin RS (2013). "Effects of Fructose vs Glucose on Regional Cerebral Blood Flow in Brain Regions Involved With Appetite and Reward Pathways." JAMA.* ***309****(1):63. doi:10.1001/jama.2012.116975.*

30. a, bBota DA, Davies KJA (2002). "Lon Protease Preferentially Degrades Oxidized Mitochondrial Aconitase by an ATP-Stimulated Mechanism." Nat Cell Biol. **4**(9):674–80. doi:10.1038/ncb836.

31. a, bChoi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES, Lee KY, Lee BH, Johnson RJ, Kang DH (2014). "Uric Acid Induces Fat Accumulation Via Generation of Endoplasmic Reticulum Stress and SREBP-1c Activation in Hepatocytes." Lab Invest. **94**(10):1114–25. doi:10.1038/labinvest.2014.98.

32. a, b, c, d, e, f, g, h, i, j, kNgo J, Choi DW, Stanley IA, Stiles L, Molina AJA, Chen PH, Lako A, Sung ICH, Goswami R, Kim MY, Miller N, Baghdasarian S, Kim-Vasquez D, Jones AE, Roach B, Gutierrez V, Erion K, Divakaruni AS, Liesa M, Danial NN, Shirihai OS (2023). "Mitochondrial Morphology Controls Fatty Acid Utilization by Changing CPT1 Sensitivity to Malonyl-CoA." EMBO J. **42**(11):e2022111901. doi:10.15252/embj.2022111901.

33. a, b, c, d, eMamikutty N, Thent ZC, Suhaimi FH (2015). "Fructose-Drinking Water Induced Nonalcoholic Fatty Liver Disease and Ultrastructural Alteration of Hepatocyte Mitochondria in Male Wistar Rat." BioMed Res Int. **2015**:895961. doi:10.1155/2015/895961.

34. a, b, cSánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ (2012). "Uric Acid-Induced Endothelial Dysfunction Is Associated With Mitochondrial Alterations and Decreased Intracellular ATP Concentrations." Nephron Exp Nephrol. **121**(3-4):e71–8. doi:10.1159/000345509.

35. a, b, c, d, ePoljsak B, Milisav I (2016). "NAD+ as the Link Between Oxidative Stress, Inflammation, Caloric Restriction, Exercise, DNA Repair, Longevity, and Health Span." Rejuvenation Res. **19**(5):406–413. doi:10.1089/rej.2015.1767.

36. a, bTang L, Xu Y, Wei Y, He X (2017). "Uric Acid Induces the Expression of TNF-α Via the ROS-MAPK-NF-κB Signaling Pathway in Rat Vascular Smooth Muscle Cells." Mol Med Rep. **16**(5):6928–34. doi:10.3892/mmr.2017.7405.

37. a, bIqbal J, Zaidi M (2007). "CD38 Is Required for Priming by TNF-Alpha: A Mechanism for Extracellular Coordination of Cell Fate." Am J Physiol Renal Physiol. **293**(1):F153–60.

38. a, b, c, d, e, f, g, h, iCovarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Heckenbach I, Kwok R, Wiley CD, Wong HS, Gibbs E, Iyer SS, Basisty N, Wu Q, Kim IJ, Silva E, Vitangcol K, Shin KO, Lee YM, Riley R, Ben-Sahra I, Ott M, Schilling B, Scheibye-Knudsen M, Ishihara K, Quake SR, Newman J, Brenner C, Campisi J, Verdin E (2020). "Senescent Cells Promote Tissue NAD+ Decline During Ageing Via the Activation of CD38+ Macrophages." Nat Metab. **2**(11):1265–83. doi:10.1038/s42255-020-00305-3.

39. ^Fanet H, Capuron L, Castanon N, Calon F, Vancassel S (2021). "Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry." Curr Neuropharmacol. **19**(5):591–609. doi:10.2174/1570159X1866620072910

3529.

40. ^*Cronin SJF, et al. (2023). "Tetrahydrobiopterin Deficiency Increases Sensitivity to Neurodegenerative Stressors." Nat Commun.* ***14****:1234.*

41. a, b, c, d*Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S, Aird KM, Iwasaki O, Kossenkov AV, Schultz D, Noma KI, Baur JA, Schug Z, Tang HY, Speicher DW, David G, Zhang R (2019). "NAD+ Metabolism Governs the Proinflammatory Senescence-Associated Secretome." Nat Cell Biol.* ***21****(3):397–407. doi:10.1038/s41556-019-0287-4.*

42. a, b, c, d, e*Wagh AR, Glickman MH (2025). "Molecular Mechanisms Underlying p62-Dependent Secretion of the Alzheimer-Associated Ubiquitin Variant UBB*$^{+1}$*." Proc Natl Acad Sci U S A.* ***122****(50):e2504528122. doi:10.1073/pnas.2504528122.*

43. ^*Navarro VM (2020). "Metabolic Regulation of Kisspeptin — the Link Between Energy Balance and Reproduction." Nat Rev Endocrinol.* ***16****(8):407–20. doi:10.1038/s41574-020-0363-7.*

44. a, b, c, d, e, f, g, h*Wahab F, Atika B, Ullah F, Shahab M, Behr R (2018). "Metabolic Impact on the Hypothalamic Kisspeptin-Kiss1r Signaling Pathway." Front Endocrinol (Lausanne).* ***9****:123. doi:10.3389/fendo.2018.00123.*

45. a, b*Chini CCS, Hogan K, Warner G, Tarragó MG, Peclat TR, Tchkonia T, Kirkland JL, Chini E (2019). "The NADase CD38 Is Induced by Factors Secreted From Senescent Cells Providing a Potential Link Between Senescence and Age-Related Cellular NAD+ Decline." Biochem Biophys Res Commun.* ***513****(2):486–493. doi:10.1016/j.bbrc.2019.03.199.*

46. a, b, c, d*Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA (2013). "Sugar, Uric Acid, and the Etiology of Diabetes and Obesity." Diabetes.* ***62****(10):3307–15. doi:10.2337/db12-1814.*

47. a, b, c, d*Luo S, Monterosso JR, Sarpelleh K, Page KA (2015). "Differential Effects of Fructose Versus Glucose on Brain and Appetitive Responses to Food Cues and Decisions for Food Rewards." Proc Natl Acad Sci U S A.* ***112****(20):6509–14. doi:10.1073/pnas.1503358112.*

48. ^*Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glassock RJ, Shimada M, Roncal C, Nakagawa T (2009). "Hypothesis: Could Excessive Fructose Intake and Uric Acid Cause Type 2 Diabetes?" Endocr Rev.* ***30****(1):96–116. doi:10.1210/er.2008-0033.*

49. ^*Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, Andreozzi F, Mannino GC, Sesti G (2017). "Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-κB Signaling Pathway in HepG2 Cells." Arterioscler Thromb Vasc Biol.* ***37****(6):1241–9. doi:10.1161/ATVBAHA.117.309128.*

50. ^Hill JW, Elmquist JK, Elias CF (2008). "Hypothalamic Pathways Linking Energy Balance and Reproduction." Am J Physiol Endocrinol Metab. **294**(5):E827–E832. doi:10.1152/ajpendo.00670.2007.

51. a, bAbizaid A, Horvath TL (2008). "Brain Circuits Regulating Energy Homeostasis." Regul Pept. **149**(1-3):3–10. doi:10.1016/j.regpep.2007.10.006.

52. ^Diggle CP, Shires M, Leitch D, Brooke D, Carr IM, Markham AF, Hayward BE, Asipu A, Bonthron DT (2009). "Ketohexokinase: Expression and Localization of the Principal Fructose-Metabolizing Enzyme." J Histochem Cytochem. **57**(8):763–74. doi:10.1369/jhc.2009.953190.

53. a, b, cSchwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, Patterson BW, Gugliucci A, Lustig RH, Mulligan K (2017). "Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity." Gastroenterology. **153**(3):743–52. doi:10.1053/j.gastro.2017.05.043.

54. a, b, cWilson DF (2013). "Regulation of Cellular Metabolism: Programming and Maintaining Metabolic Homeostasis." J Appl Physiol. **115**(11):1583–8. doi:10.1152/japplphysiol.00894.2013.

55. ^Ducloux D (2024). "Fructokinase Inhibition to Prevent Kidney Disease." Clin J Am Soc Nephrol. **19**(6):807–9. doi:10.2215/CJN.0000000000000442.

56. ^Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H (2011). "Flavonoids as Inhibitors of Human CD38." Bioorg Med Chem Lett. **21**(13):3939–42. doi:10.1016/j.bmcl.2011.05.022.

57. ^Lim H, Park H, Kim HP (2015). "Effects of Flavonoids on Senescence-Associated Secretory Phenotype Formation From Bleomycin-Induced Senescence in BJ Fibroblasts." Biochem Pharmacol. **96**(4):337–48. doi:10.1016/j.bcp.2015.06.013.

58. ^Trinh CH, Asipu A, Bonthron DT, Phillips SEV (2009). "Structures of Alternatively Spliced Isoforms of Human Ketohexokinase." Acta Crystallogr D Biol Crystallogr. **65**(3):201–11. doi:10.1107/S0907444908041115.

59. ^Zhu M, Sun Y, Su Y, Guan W, Wang Y, Han J, Wang S, Yang B, Wang Q, Kuang H (2024). "Luteolin: A Promising Multifunctional Natural Flavonoid for Human Diseases." Phytother Res. **38**(7):3417–43. doi:10.1002/ptr.8217.

Declarations

Funding: This research was conducted independently and received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Potential competing interests: C.R.M. is a founder and principal of LIV3 Health, which develops nutritional protocols and dietary supplements. This work is a theoretical synthesis of public literature and does not report clinical data or make efficacy claims for specific commercial products.